← Back to Search

HMG-CoA Reductase Inhibitor

Rosuvastatin + Selpercatinib for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose up to 72 hours post-dose
Awards & highlights

Study Summary

This trial will test how selpercatinib affects levels of rosuvastatin in healthy people, and how safe and tolerable the combination is. It will last about 26 days.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose up to 72 hours post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose up to 72 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin

Trial Design

1Treatment groups
Experimental Treatment
Group I: Rosuvastatin + SelpercatinibExperimental Treatment2 Interventions
Rosuvastatin administered orally on day 1 followed by rosuvastatin administered with selpercatinib on day 5 orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rosuvastatin
2019
Completed Phase 4
~3150
Selpercatinib
2021
Completed Phase 1
~600

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,889 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,648 Total Patients Enrolled

Media Library

Rosuvastatin (HMG-CoA Reductase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05906836 — Phase 1
Healthy Subjects Research Study Groups: Rosuvastatin + Selpercatinib
Healthy Subjects Clinical Trial 2023: Rosuvastatin Highlights & Side Effects. Trial Name: NCT05906836 — Phase 1
Rosuvastatin (HMG-CoA Reductase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05906836 — Phase 1
~17 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top